Loss of Lgals3 Protects Against Gonadectomy-Induced Cortical Bone Loss in Mice

Kevin A Maupin1, Daniel Dick1, Johan Lee1

  • 1Program for Skeletal Disease and Tumor Microenvironment and Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI, USA.

Insights

Targeting galectin-3 (Lgals3-KO) may protect against bone loss after sex hormone loss. Lgals3-KO mice show altered bone responses to estrogen and androgens, suggesting a therapeutic target.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Molecular Biology

Background:

  • Sex hormone deprivation, common after menopause or prostate cancer therapy, causes bone loss.
  • Galectin-3 (Lgals3) deletion in mice (Lgals3-KO) shows sex-dependent effects on bone mass.
  • Novel therapies are needed to counteract bone loss due to diminished sex hormones.

Purpose of the Study:

  • To investigate the role of estrogen (E2) and androgen (DHT) in the bone phenotype of Lgals3-KO mice.
  • To understand the sex-dependent mechanisms underlying bone loss in Lgals3-KO mice.

Main Methods:

  • Male and female wild-type and Lgals3-KO mice underwent gonadectomy with or without E2 or DHT hormone rescue.
  • Bone mass, bone area (B.Ar), total area (T.Ar), and osteoblast number were compared between groups.

Main Results:

  • Lgals3-KO mice exhibited greater cortical bone expansion and reduced bone loss after gonadectomy.
  • DHT increased bone parameters in wild-type but not Lgals3-KO mice.
  • Estrogen (E2) rescue more effectively increased bone area in Lgals3-KO females, but failed to repress total area expansion.

Conclusions:

  • Galectin-3 influences the sex-dependent bone response to sex hormone deprivation.
  • Targeting galectin-3 may offer a novel therapeutic strategy for preventing bone loss associated with low sex hormones.